Ibandronate

Indications & Dose:

Osteoporosis, postmenopausal - prophylaxis and treatment

Osteoporosis, post organ transplant - treatment

Skeletal metastases, prostate cancer - pain relief 

• BY MOUTH

Adult and Child>16 yr

• PO 150mg once daily for one month  with only plain water; no dosage adjustment necessary for hepatic or renal impairment or geriatric patients

Post menopausal Ostoporosis:

3mg every 3 months over 15-30 seconds 

Contraindications:

Uncorrected hypocalcemia; inability to stand or sit upright for at least 60 minutes post dosage 

Side Effects:

CNS: Headache (6.5%), dizziness, vertigo, nerve root lesion
EENT: Ocular inflammation (uveitis, scleritis)
GI: Dyspepsia (11.9%), diarrhea (7%), tooth disorder, vomiting, nausea, gastritis, esophagitis, reversible hepatocellular injury (increased enzymes)

GU: Urinary tract infection (6%)
METAB: Hypercholesterolemia, hypomagnesaemia, hypophosphatemia
MS: Back pain ( 14%), myalgia (6%), joint disorder, arthritis
RESP: Bronchitis ( 1 0%), pneumonia (6%), pharyngitis
MISC: Fever (9%), flu-like symptoms 

Cautions:

Precautions:

Concomitant upper gastrointestinal disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer; severe renal impairment (creatinine clearance <30 ml/min) 

Interaction:

Drugs

Antacids: calcium and other multivalent cations (aluminum, magnesium, iron): Reduced absorption

Food (including coffee and juice): Decreases bioavailability drastically (see pharmacokinetics)

Aspirin, nonsteroidal antiinflammatory drugs: Theoretical increased risk of gastropathy
 

Warnings:

Adverse Effects:

Lactations:

Pregnancy category C; breast milk excretion unknown 

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: